DMT harm reduction (risk information, not endorsement)
Harm reduction is not endorsement. This page is risk information for adults who encounter DMT or 5-MeO-DMT topics in research, news, or personal contexts. dmt.clinic is operated by AdvancedCare USA Inc. It is not a clinic, does not provide medical advice, does not refer patients to any provider, and does not sell substances or paraphernalia.
N,N-DMT and 5-MeO-DMT are Schedule I controlled substances under U.S. federal law (21 U.S.C. §812; 21 C.F.R. §1308.11; as of 2026-07-21). Possession outside narrow lawful channels (FDA/DEA-authorized research; limited named religious exemptions) is illegal. See legal status.
Hard boundary — what this page will not do
| We will discuss | We will not publish |
|---|---|
| Documented categories of harm | Dose amounts or “common dose” charts |
| Why certain drug combinations are dangerous | Route, preparation, or “set and setting” how-tos |
| When to seek emergency help | “If you are going to use it anyway, do X” protocols |
| Links to external harm-reduction orgs | Provider / underground / retreat finders |
If a reader needs instructions, this is the wrong website — by design.
Documented risk categories
Cardiovascular and autonomic stress
Serotonergic psychedelics can raise blood pressure and heart rate. 5-MeO-DMT is particularly associated in case-report and toxicology literature with severe hypertension and with cardiovascular and respiratory adverse events, including deaths discussed in published case series and toxicology reviews. Uncontrolled settings, unknown purity, and poly-drug use worsen risk. This is why research protocols use medical monitoring — and why “short trip = low risk” is a false comfort.
Psychological adverse events
Reported harms include acute panic, confusion, prolonged anxiety or dysphoria after the acute period, and rare severe psychiatric crises. People with a personal or family history of psychosis-spectrum illness are often excluded from psychedelic trials for safety reasons; that exclusion criterion is a signal that risk is not theoretical. This site does not assess your history — a licensed clinician who knows you does.
Serotonin syndrome and drug–drug interactions
Combining serotonergic agents can precipitate serotonin syndrome, a medical emergency (agitation, autonomic instability, neuromuscular findings — seek emergency care). Agents of particular concern in the literature and clinical teaching include:
- MAOIs (including pharmaceutical MAOIs and plant β-carbolines discussed in ayahuasca ethnobotany)
- SSRIs / SNRIs and other serotonergic antidepressants
- Lithium
- Other serotonergic or monoaminergic drugs (including some OTC and illicit combinations)
Framing: we list interaction classes so readers understand why mixing can be dangerous. We do not publish washout schedules, “safe waiting times,” or combination protocols. Medication decisions belong with a clinician who has your full list.
HPPD and persistent phenomena
Hallucinogen persisting perception disorder (HPPD) and related lasting sensory disturbances are reported after various hallucinogens. Incidence estimates vary; the educational point is that “it’s over when the acute effect ends” is not guaranteed for every person.
Unknown identity and adulteration
Materials sold outside regulated pharmaceutical manufacturing are not quality-assured. Misidentified substances, contaminants, and unexpected potency are recurring themes in drug-checking programs. See external resources below — we link organizations; we do not operate a testing service.
Contraindication awareness (not a screening tool)
Research protocols and clinical reviews commonly flag elevated concern when any of the following are present. This is awareness, not clearance to use if the box is unchecked:
- Known cardiac disease, uncontrolled hypertension, or serious arrhythmia history
- Personal or first-degree family history of psychotic disorders
- Current serotonergic medications or recent MAOI exposure
- Acute suicidality or severe instability without clinical support
- Pregnancy (generally an exclusion in trials; not a research playground)
If any of these apply and you are distressed, use crisis channels — not substance experimentation.
When to seek emergency help
Use 911 (or local emergency services) for suspected overdose, severe chest pain, seizures, unresponsiveness, severe hyperthermia, or signs of serotonin syndrome.
Use 988 (call or text) or text HOME to 741741 (Crisis Text Line) for mental-health crisis support. Those resources appear in the site-wide crisis notice on every page. They are for safety, not for finding DMT.
External resources (links, not instructions)
We point to established organizations. Their materials may change; verify on their sites (links checked 2026-07-21):
- MAPS (Multidisciplinary Association for Psychedelic Studies) — research and education context; not a vendor
- DanceSafe — harm-reduction education and drug-checking advocacy
- findtreatment.gov — U.S. treatment locator for substance use disorders (clinical treatment, not psychedelic access)
- ClinicalTrials.gov — research studies only; see clinical research
Talk to a clinician who knows your history about interactions and mental-health risk. Do not substitute this page for care.
Research context vs street risk
FDA/DEA-authorized trials monitor vital signs, screen for contraindicated medications, and define stop rules. That infrastructure is part of why research is not the same as uncontrolled use. Citing a trial paper does not recreate those safeguards. Observational surveys of non-clinical use can report positive subjective outcomes and still under-count severe rare events — selection bias and under-reporting are real.
If your interest is scientific, start with peer-reviewed methods papers and ClinicalTrials.gov protocol records, not anecdote threads. If your interest is personal mental health care, talk to a licensed clinician about legal, available options; this site will not bridge you to DMT outside research law.
How this fits the rest of the site
- Lawful research framing: clinical research · homepage trial finder
- Legal status without availability implication: legal status
- Molecule differences without sourcing: DMT vs 5-MeO-DMT · pharmacology
Sources (checked 2026-07-21)
- Toxicology and case-report literature on 5-MeO-DMT adverse cardiovascular/respiratory events.
- Clinical teaching on serotonin syndrome (serotonergic drug combinations).
- HPPD literature across classical hallucinogens.
- MAPS and DanceSafe public harm-reduction education pages.
- DEA/eCFR Schedule I status for N,N-DMT and 5-MeO-DMT.
- Clinical trial exclusion-criteria patterns (psychosis history, serotonergic meds, cardiac disease) as safety signals — not as DIY screening.
Last editorial check: 2026-07-21. Risk information only. Not medical advice. Not endorsement of use.